The penetration of moxifloxacin (BAY 12-8039) into the excretory pancreatic secret after intravenous application.

Trial Profile

The penetration of moxifloxacin (BAY 12-8039) into the excretory pancreatic secret after intravenous application.

Completed
Phase of Trial: Phase I

Latest Information Update: 07 Sep 2016

At a glance

  • Drugs Moxifloxacin (Primary) ; Moxifloxacin (Primary)
  • Indications Bacterial infections; Pancreatitis
  • Focus Pharmacokinetics
  • Most Recent Events

    • 08 Sep 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top